STEP: Sleep and Tracking Effects in Pregnancy Study

Sponsor
University of North Carolina, Chapel Hill (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04173559
Collaborator
(none)
250
1
2
41.4
6

Study Details

Study Description

Brief Summary

Purpose: The investigators hypothesize that a simple, personalized, smartphone-based activity intervention using a wrist-based activity tracker will help high risk pregnant women reduce their stress during pregnancy.

Participants: Pregnant women enrolled in prenatal care at the University of North Carolina who have a documented moderate or high level of perceived stress ( ≥ 14) and are at high risk for adverse pregnancy outcomes due to body mass index of ≥ 30 kg/m2 or history of gestational hypertension, preeclampsia, intrauterine growth restriction, or preterm birth <37 weeks' in a prior pregnancy.

Procedures: Women meeting inclusion criteria will be recruited through the University of North Carolina prenatal care clinics. They will be contacted for possible participation at regularly scheduled prenatal visits and/or ultrasound. They may also be contacted for possible participation by remote methods (e.g., Telehealth). Women who are enrolled will complete validated dietary, stress, sleep, and body image questionnaires. Enrolled women will then be randomized to receive standard obstetrical care or enhanced counseling. All participants will receive a wrist-based activity tracker. Maternal blood sample for biochemical markers of stress and gene expression will be obtained at the initial visit; a followup blood sample will be obtained later in pregnancy, and a small portion of the placenta saved at delivery. Maternal and neonatal outcomes will be compared between groups.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Activity Intervention
N/A

Detailed Description

During pregnancy, women regularly interact with healthcare professionals, an often untapped resource and opportune time to minimize stress and optimize weight gain, nutrition, and activity, positively impacting outcomes and lifelong health. The overarching hypothesis of this study is that a simple, personalized, smartphone-based activity intervention using a wrist-based activity tracker will help high risk pregnant women increase their activity level during pregnancy, reduce stress, and optimize gestational weight gain and biometric parameters. Importantly, the investigators propose that women can be engaged in care via a simple, personalized text-message based intervention.

Women will be enrolled early in pregnancy and followed prospectively. All women will receive a wrist-based activity tracker. Some women (those randomized to receive individualized counseling) will receive weekly text messages based on their activity and sleep in the prior week. Other women will not receive any specific instructions regarding activity level. The investigators will follow their outcomes prospectively. Biologic samples (including blood, urine, vaginal swabs, placental tissue) will be collected at enrollment and at delivery.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
250 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized Controlled TrialRandomized Controlled Trial
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Improving Perinatal Outcomes Through Activity and Sleep Tracking
Anticipated Study Start Date :
Dec 1, 2021
Anticipated Primary Completion Date :
May 14, 2025
Anticipated Study Completion Date :
May 14, 2025

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Usual care

Women randomized to this group will receive no guidance regarding exercise / activity / sleep during pregnancy.

Experimental: Activity Intervention

Women randomized to this group will receive detailed information and reminders about physical activity and sleep in pregnancy. .

Behavioral: Activity Intervention
After 1 week of baseline activity is obtained, participants will be contacted with personalized activity goals that are 10% higher than their previous weeks' activity levels. They will also receive feedback regarding sleep if they are not averaging at least 6 hours per night or if they are waking more than twice per night. Participants will also receive weekly text reminders and encouraging feedback, and will receive additional counseling in person at regularly scheduled prenatal visits until delivery.

Outcome Measures

Primary Outcome Measures

  1. Reduction in Perceived Maternal Stress [through delivery, an average of 7 months per participant]

    Perceived stress score will be calculated using a validated 10-question stress scale; score = 14 indicates moderate stress

  2. Proportion of women with adverse perinatal outcomes [outcome will be ascertained at delivery]

    The investigators will define adverse pregnancy outcomes as a composite of preterm birth <37 weeks, intrauterine growth restriction, preeclampsia, and placental abruption; outcomes will be compared between randomization groups.

Secondary Outcome Measures

  1. Number of activity goals met by personalized activity level group [through delivery, an average of 7 months per participant]

    Proportion of weekly activity goals that were successfully met by women randomized to personalized activity group

  2. Mean Daily steps [through delivery, an average of 7 months per participant]

    Mean number of daily steps; amount will be compared between randomization groups.

  3. Median Daily steps [through delivery, an average of 7 months per participant]

    median number of daily steps; amount will be compared between randomization groups.

  4. Mean 'Moderate' or greater physical activity [through delivery, an average of 7 months per participant]

    Mean number of weekly minutes of 'moderate' or 'intense' physical activity as registered by the wrist-based activity monitor; amount will be compared between randomization groups.

  5. Median 'Moderate' or greater physical activity [through delivery, an average of 7 months per participant]

    median number of weekly minutes of 'moderate' or 'intense' physical activity as registered by the wrist-based activity monitor; amount will be compared between randomization groups.

  6. Mean Nightly sleep minutes [through delivery, an average of 7 months per participant]

    Mean number of sleep minutes per night; amount will be compared between randomization groups.

  7. Median Nightly sleep minutes [through delivery, an average of 7 months per participant]

    median number of sleep minutes per night; amount will be compared between randomization groups.

  8. Median resting heart rate parameters [through delivery, an average of 7 months per participant]

    The change in the median resting heart rate level and nadir of the resting heart rate (in beats per minute), between enrollment and delivery ; amount will be compared between randomization groups.

  9. Mean Resting heart rate parameters [through delivery, an average of 7 months per participant]

    The change in the mean resting heart rate level and nadir of the resting heart rate (in beats per minute), between enrollment and delivery ; amount will be compared between randomization groups.

  10. Median Body composition change during study - total body water [through reassessment of body composition at 16 weeks after randomization, an average of 4 months per participant.]

    The change in median total body water measurements between enrollment and re-assessment at 8 and 16 weeks (as applicable, if still pregnant) after enrollment will be compared between randomization groups.

  11. Mean Body composition change during study - total body water [through reassessment of body composition at 16 weeks after randomization, an average of 4 months per participant.]

    The change in mean total body water measurements between enrollment and re-assessment at 8 and 16 weeks (as applicable, if still pregnant) after enrollment will be compared between randomization groups.

  12. Median Body composition change during study - percent body fat [through reassessment of body composition at 16 weeks after randomization, an average of 4 months per participant.]

    The change in median percent body fat measurements between enrollment and re-assessment at 8 and 16 weeks (as applicable, if still pregnant) after enrollment will be compared between randomization groups.

  13. Mean Body composition change during study - percent body fat [through reassessment of body composition at 16 weeks after randomization, an average of 4 months per participant.]

    The change in mean percent body fat measurements between enrollment and re-assessment at 8 and 16 weeks (as applicable, if still pregnant) after enrollment will be compared between randomization groups.

  14. Gestational weight gain [through delivery, an average of 7 months per participant]

    The amount of weight gained by each participant during pregnancy, in pounds. outcomes will be compared between randomization groups.

  15. Gestational weight gain, per week after study enrollment [through delivery, an average of 7 months per participant]

    The amount of weight gained per week by each participant, in pounds, between study enrollment and delivery. outcomes will be compared between randomization groups.

  16. Proportion of women with gestational diabetes mellitus [through delivery, an average of 7 months per participant.]

    The diagnosis of gestational diabetes mellitus during pregnancy, using standard criteria as set forth by American College of Obstetricians and Gynecologists. outcomes will be compared between randomization groups.

  17. Proportion of women with hypertensive complications of pregnancy [through 6 weeks' postpartum, an average of 7 months per participant]

    The diagnosis of gestational hypertension, preeclampsia, or eclampsia, using standard American College of Obstetricians and Gynecologists diagnostic criteria. outcomes will be compared between randomization groups.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 51 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • At high risk for adverse pregnancy outcomes, due to either body mass index ≥ 30 kg/m^2, or a prior history of preeclampsia, intrauterine growth restriction or preterm birth prior to 37 weeks' gestation in a previous pregnancy and a perceived stress score of >/= 14 (10-question scale)

  • Gestational age of 8.0 to 19.9 weeks' gestation using American College of Obstetricians and Gynecologists dating criteria (combination of ultrasound and menstrual dating, as available)

  • Current singleton viable intrauterine pregnancy. Spontaneous reduction of twin to singleton gestation is allowable provided it occurred prior to 14 weeks' gestation.

  • No structural abnormalities or aneuploidy

  • Ability to communicate in and provide consent in English

  • Maternal age 18 to 51 years of age

  • Owns smartphone compatible with wrist-based activity tracker (over 200 devices supported)

Exclusion Criteria:
  • Women pregnant with multifetal gestations

  • Women who have a medical condition where a modest increase in low-impact activity is contraindicated (at the discretion of the woman's treating physician)

  • Planned delivery prior to 36 weeks' of gestation

  • Unwilling to wear wrist-based activity tracker for at least 6 out of 7 days per week

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of North Carolina Chapel Hill North Carolina United States 27599

Sponsors and Collaborators

  • University of North Carolina, Chapel Hill

Investigators

  • Principal Investigator: Tracy A Manuck, MD, University of North Carolina, Chapel Hill

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier:
NCT04173559
Other Study ID Numbers:
  • 18-2434
First Posted:
Nov 22, 2019
Last Update Posted:
Nov 8, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 8, 2021